Vitamin D Inhibition of the Prostaglandin Pathway as Therapy for Prostate Cancer

Nutrition Reviews

Volumn 65, Issue SUPPL.2, 2007, Pages

  Feldman, David ^a   Krishnan, Aruna ^a   Moreno, Jacqueline ^a   Swami, Srilatha ^a   Peehl, Donna M ^a   Srinivas, Sandy ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; VITAMIN D;

DRUG EFFECT; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MALE; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDINS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 35148861063     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2007.tb00335.x     Document Type: Article

References (23)

1. Badawi AF. The role of prostaglandin synthesis in prostate cancer. BJU Int 2000;85:S451-S462.
2. Hussain T., Gupta S., Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003;191:S125-S135.
3. Moreno J., Krishnan AV, Swami S., Nonn L., Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005;65:S7917-S7925.
4. Gupta S., Srivastava M., Ahmad N., Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:S73-S78.
5. Yoshimura R., Sano H., Masuda C., et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:S589-S596.
6. Zha S., Gage WR, Sauvageot J., et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61:S8617-S8623.
7. Wagner M., Loos J., Weksler N., et al. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun 2005;332:S800-S807.
8. Cohen BL, Gomez P., Omori Y., et al. Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 2006;119:S1082-S1087.
9. Yan M., Rerko RM, Platzer P., et al. 15-Hydroxypros-taglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 2004;101:S17468-S17473.
10. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:S661-S690.
11. Chen Y., Hughes-Fulford M. Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 2000;82:S2000-S2006.
12. Krishnan AV, Shinghal R., Raghavachari N., Brooks JD, Peehl DM, Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004;59:S243-S251.
13. Peehl DM, Shinghal R., Nonn L., et al. Molecular activity of 1, 25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 2004;92:S131-S141.
14. Topol EJ. Failing the public health: Rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:S1707-S1709.
15. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:S1520-S1528.
16. Beer TM, Lemmon D., Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003;97:S1217-S1224.
17. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus do-cetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25:S669-S674.
18. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 2003;88:S363-S371.
19. Peehl DM, Krishnan AV, Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 2003;133: S2461S-S2469S.
20. Stewart LV, Weigel NL Vitamin D and prostate cancer. Exp Biol Med (Maywood) 2004;229:S277-S284.
21. Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004;89-90:S519-S526.
22. Krishnan AV, Moreno J., Nonn L., et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 2007;103:S694-S702.
23. Krishnan AV, Moreno J., Nonn L., Swami S., Peehl DM, Feldman D. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res 2007;in press.